Blog
Freelance.com: Freelance.com generates over €800m in revenue in 2022
Freelance.com: Freelance.com generates over €800m in revenue in 2022
EQS-News: PATRIZIA SE: Strong growth in AUM to EUR 59.1bn (+21.6% y-o-y) in FY 2022 demonstrates resilience of PATRIZIA’s real asset investment management platform
EQS-News: PATRIZIA SE: Strong growth in AUM to EUR 59.1bn (+21.6% y-o-y) in FY 2022 demonstrates resilience of PATRIZIA’s real asset investment management platform
EQS-News: Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion
EQS-News: Capital Markets Day 2023: BRAIN Biotech AG to build an international multi-niche enzyme and food ingredients champion
Rights and Issues Investment Trust PLC: Director Declaration
Rights and Issues Investment Trust PLC: Director Declaration
Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc
Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc
Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Rights and Issues Investment Trust PLC: NAV-Net Asset Value(s)
Rights and Issues Investment Trust PLC: NAV-Net Asset Value(s)
Chelverton UK Dividend Trust plc: NAV-Net Asset Value(s)
Chelverton UK Dividend Trust plc: NAV-Net Asset Value(s)
EQS-News: Francotyp-Postalia Holding AG: Acquisition of treasury shares – 17th interim report
EQS-News: Francotyp-Postalia Holding AG: Acquisition of treasury shares – 17th interim report
EQS-Adhoc: Gigaset AG: Currency and short-term material effects in Q4 have less impact on 2022 outlook than expected. EBITDA forecast for 2022 is raised.
EQS-Adhoc: Gigaset AG: Currency and short-term material effects in Q4 have less impact on 2022 outlook than expected. EBITDA forecast for 2022 is raised.
Chelverton UK Dividend Trust plc: Monthly Factsheet
Chelverton UK Dividend Trust plc: Monthly Factsheet
Form 8.3 - Maitland Institutional Services Limited: Re Purple Bricks Group PLC
Form 8.3 - Maitland Institutional Services Limited: Re Purple Bricks Group PLC
EQS-News: Smartbroker Holding AG: Invitation to the Earnings Call for the preliminary FY 2022 results
EQS-News: Smartbroker Holding AG: Invitation to the Earnings Call for the preliminary FY 2022 results
EQS-News: Confirmation of the figures and further development of the sales strategy
EQS-News: Confirmation of the figures and further development of the sales strategy
Convatec Group PLC: Director/PDMR Shareholding
Convatec Group PLC: Director/PDMR Shareholding
EQS-News: First Phosphate forges alliance with European phosphorus chemistry technology leader
EQS-News: First Phosphate forges alliance with European phosphorus chemistry technology leader
EQS-News: Energy Recovery’s PX G1300 Technology Unveiled as Key Component in Epta Group’s Next-Generation CO2 Refrigeration System
EQS-News: Energy Recovery’s PX G1300 Technology Unveiled as Key Component in Epta Group’s Next-Generation CO2 Refrigeration System
Turkiye Garanti Bankasi A.S.: Announcement regarding Fitch Ratings
Turkiye Garanti Bankasi A.S.: Announcement regarding Fitch Ratings
Nordea Bank Abp: Transaction in Own Shares
Nordea Bank Abp: Transaction in Own Shares
Biophytis initiates the regulatory process for an early access authorization in France from the French National Authority for Health (HAS) for the treatment with Sarconeos (BIO101) of severe forms of
Biophytis initiates the regulatory process for an early access authorization in France from the French National Authority for Health (HAS) for the treatment with Sarconeos (BIO101) of severe forms of
Transaction in Own Shares
Transaction in Own Shares
METAVISIO: METAVISIO (THOMSON Computing) sees improved EBITDA margin in 2022 versus 2021.
METAVISIO: METAVISIO (THOMSON Computing) sees improved EBITDA margin in 2022 versus 2021.
EQS-News: DEFENCE’S PIPELINE ADVANCES TO MULTIPLE PHASE I CLINICAL TRIALS
EQS-News: DEFENCE’S PIPELINE ADVANCES TO MULTIPLE PHASE I CLINICAL TRIALS


